National Cancer Institute (nci)

This study looks at whether giving the HPV vaccine on a different schedule (a first shot now and a booster later) works well in healthy 9-11 year-old girls and boys. The goal is to see if the body still makes enough antibodies to protect against HPV, a virus that can cause certai…

This study tests a vaccine that helps the body's immune system recognize and attack advanced colon polyps, which can turn into cancer. About 110 people who have had these polyps removed will receive either the vaccine or a placebo. The goal is to see if the vaccine boosts immune …

This study tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer and whose tumors are PD-L1 negative. The goal is to see if the vaccine can train the immune system to recognize and…

This study tests a vaccine called Nous-209 in 45 people with Lynch syndrome, a genetic condition that raises the risk of colon and other cancers. The vaccine is made from man-made copies of proteins that cancer cells produce, aiming to teach the immune system to recognize and att…

This phase II trial is testing the drug defactinib in 35 patients whose advanced cancers have a specific genetic change called an NF2 mutation. The drug works by blocking a protein that may help these cancer cells grow. Researchers want to see if defactinib can shrink tumors or s…

This study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…

This phase II trial is testing the drug palbociclib in 43 patients with advanced cancers that have extra copies of the CDK4 or CDK6 genes. Palbociclib works by blocking signals that tell cancer cells to multiply. The study aims to see if the drug can shrink tumors or slow their g…

This study tests whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) helps shrink tumors or slow cancer growth in people with advanced pancreatic cancer who have BRCA or PALB2 gene mutations. About 83 participants will receive either the chemo a…

This phase 2 trial tests whether adding the drug decitabine to standard chemotherapy improves remission rates in adults with acute myeloid leukemia (AML) who have less favorable genetic risk. Decitabine is given before chemo to try to make cancer cells more sensitive. About 178 p…

This phase 3 trial tests whether adding the immunotherapy drug nivolumab to standard chemo-immunotherapy helps people with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). PMBCL is a rare cancer that starts in the chest. The study includes 244 participants aged 2 and …

This phase 2 study tests whether combining two oral drugs, olaparib and cediranib, can help control recurrent ovarian, peritoneal, or fallopian tube cancer. About 70 participants with high-grade serous or endometrioid cancers are enrolled. The goal is to see if the combination ca…

This early-phase trial tests the safety and best dose of two drugs, vorinostat and azacitidine, given together to people with advanced nasopharyngeal cancer or nasal NK-T cell lymphoma that has returned or spread. The study enrolls 18 adults whose cancer cannot be removed by surg…

This early-phase trial tests a combination of copanlisib (a targeted drug) with nivolumab (an immunotherapy) in people with advanced solid tumors or lymphoma. Some participants will also receive a third drug, ipilimumab. The main goals are to find the safest dose and to monitor s…

This phase II trial is testing the drug binimetinib in 53 people whose cancers (excluding melanoma) have a specific genetic change called an NRAS mutation. Binimetinib blocks certain proteins that help these cancer cells grow. The study aims to see if the drug can shrink tumors o…

This phase II trial tests whether adding GM-CSF (a protein that boosts immune cell production) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be removed by surgery are randomly ass…

This phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…

This early-phase trial is testing a drug called DS-8201a in 62 adults with advanced HER2-positive solid tumors that have not responded to standard treatments. The drug works by attaching to the HER2 protein on cancer cells and damaging their DNA, which may kill the cells. Researc…

This phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…

This phase 2 trial tests whether combining nilotinib (a targeted drug) with paclitaxel (a chemotherapy drug) can help patients whose solid tumors have grown despite prior taxane treatment. About 40 adults with advanced or resistant cancers will receive the combination. The study …

This phase 2 trial tests the drug cabozantinib in 90 patients with osteosarcoma or Ewing sarcoma that has returned or spread. The drug works by blocking enzymes that help cancer cells grow and by cutting off the blood supply tumors need. The main goal is to see if the cancer stop…

This phase II trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 11 patients with advanced thyroid cancer that no longer responds to radioactive iodine or prior targeted therapy. The goal is to see if this mix can shrink tumors or stop them from g…

This phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …

This study tests whether adding anetumab ravtansine (a targeted therapy that delivers chemotherapy directly to cancer cells) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for people with mesothelin-positive pleural mesothelioma. About 49 participants w…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This study tests whether adding the drug triapine to standard radiation and cisplatin chemotherapy helps women with advanced cervical or vaginal cancer live longer. About 450 women with newly diagnosed, bulky or advanced cancers are participating. The goal is to see if the combin…

This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…

This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. About 46 participants with stage II-IV diffuse large B-cell lymphoma will receive the combination. The main goals …

This phase II trial tests whether taking targeted drugs (dabrafenib and trametinib) with planned breaks works as well as taking them every day for people with advanced melanoma that has a BRAF mutation. About 280 participants will be randomly assigned to either continuous or inte…

This phase II trial tests the drug pomalidomide in about 45 people with Kaposi sarcoma, a rare skin cancer. Pomalidomide works by stopping blood vessel growth and boosting the immune system to fight cancer cells. The study aims to see how long tumors shrink and how many people re…

This early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…

This phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…

This phase II trial tests whether adding panitumumab to sotorasib works better than sotorasib alone for advanced solid tumors with a KRAS G12C mutation. About 105 adults will receive either the combination or single drug. The goal is to see if the combo slows cancer growth or shr…

This phase 2 trial tests the drug vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. Vismodegib works by blocking a growth signal in cancer cells. The study looks at how many patients have their tumors shrink or stay sta…

This study tests whether adding a drug called vorinostat to the standard R-CHOP chemotherapy regimen can better treat newly diagnosed, advanced-stage diffuse large B-cell lymphoma (DLBCL). Vorinostat works by blocking enzymes that help cancer cells grow and by cutting off their b…

This phase 2 trial tests whether adding pevonedistat to standard chemotherapy (carboplatin and paclitaxel) can shrink tumors in people with advanced bile duct cancer that has spread or cannot be removed. About 40 adults whose cancer progressed after gemcitabine-based chemo will r…

This phase 2 trial was designed to test CBX-12, a drug that delivers a cancer-killing substance directly to tumor cells, in people with metastatic colorectal cancer that had stopped responding to standard treatments. The study was withdrawn before any participants were enrolled, …

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This phase 2 trial tests whether two targeted drugs, dabrafenib and trametinib, can improve outcomes for children and young adults with a specific type of high-grade glioma (BRAF V600-mutant) after they receive radiation therapy. The study enrolls 58 participants aged 25 or young…

This early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…

This phase II trial is testing a drug called dinaciclib in 72 people with stage IV melanoma that has spread. The drug works by blocking certain enzymes that cancer cells need to grow. Researchers are looking at how well it controls the disease and what side effects occur.

This phase 2 trial tests whether giving the HPV vaccine (Gardasil 9) to adults before a kidney transplant helps their immune system fight HPV after transplant, when they must take strong anti-rejection drugs. About 51 participants will receive the vaccine and have their immune re…

This study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The goal is to see if this treatment can prevent or delay the disease from …

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This early-phase trial is testing a new drug called lintuzumab-Ac225 for people with a type of blood cancer called myelodysplastic syndrome (MDS) that hasn't responded to standard treatments. The drug is an antibody that seeks out cancer cells and delivers a small dose of radiati…

This study planned to test a combination of two drugs—tarlatamab and sacituzumab govitecan—in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to find a safe dose and see…

This phase III trial tests whether adding the immunotherapy drug nivolumab after standard chemotherapy and radiation helps people with HPV-positive throat cancer live longer without the cancer growing. About 636 patients with intermediate-risk, locally advanced disease will eithe…

This phase II/III trial tests whether adding the drug venetoclax to standard chemotherapy can lower the chance of high-grade B-cell lymphomas coming back or getting worse. The study involves 363 participants with specific aggressive lymphoma subtypes. Venetoclax blocks a protein …

This phase II trial tests the drug decitabine in 21 patients with advanced myelofibrosis, a bone marrow cancer that causes scarring and anemia. The goal is to see if decitabine can improve blood counts and reduce the need for transfusions. Researchers are also monitoring side eff…

This early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…

This phase 3 trial tests whether adding the immune-boosting drug nivolumab before and after kidney cancer surgery can prevent the cancer from coming back. About 819 patients with localized kidney cancer are randomly assigned to receive either surgery alone or surgery plus nivolum…

This study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose an…

This study tests whether combining olaparib and temozolomide works better than standard drugs (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery and has stopped responding to initial chemotherapy. About 74 pa…

This early-phase trial is testing a combination of two drugs, ibrutinib and lenalidomide, in people with B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The main goal is to find the safest dose and understand side effects. About 39 participants with d…

This phase 3 trial tests whether the immune-boosting drug pembrolizumab can help prevent bladder cancer from coming back after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer will receive either pembrolizumab or just observation. The study m…

This early-phase trial tests a combination of three drugs — bortezomib, sorafenib, and decitabine — in patients with acute myeloid leukemia (AML), especially those who are older or have hard-to-treat forms. The main goal is to find the safest dose and see how well patients tolera…

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…

This phase II trial is testing the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR mutation and have not responded to standard treatments. Afatinib works by blocking the mutated EGFR protein that helps cancer cells grow. The study ai…

This phase 2 trial tests whether combining an HPV vaccine (PRGN-2009) with the immunotherapy drug pembrolizumab can strengthen the immune system's attack on HPV-positive oropharyngeal cancer before standard treatment. Sixteen adults with newly diagnosed, HPV-related throat cancer…

This phase II trial tests whether adding MK-2206 to the standard drug bicalutamide can better control prostate cancer in men whose PSA levels are rising after initial treatment. About 108 participants will receive either the combination or bicalutamide alone. The main goal is to …

This early-stage trial is testing whether adding an experimental drug called ZEN003694 to two approved cancer drugs (cetuximab and encorafenib) can help people with a specific type of advanced colorectal cancer (BRAF V600E) that has not responded to previous treatments. The study…

This study tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce how often people with recurrent respiratory papillomatosis (RRP) need surgery to clear wart-like growths from their airways. About 21 adults who need at least two surgeries per year will rece…

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This phase 3 trial compares two treatment combinations for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. One group gets lenalidomide plus low-dose dexamethasone, while the other gets those two drugs plus bortezomib. The goal …

This early-stage trial tests a DNA vaccine called INO-8000, given with an immune booster, to see if it can help people with chronic hepatitis C fight the virus. The study involves 33 participants and focuses on safety and finding the best dose. The vaccine is delivered through in…

This early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in women with ovarian cancer that has returned after platinum treatment. The study enrolls 54 participants and focuses on finding the safest dose and monitoring side effects. If …

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This early-phase trial is testing a combination of three drugs—rituximab, lenalidomide, and ibrutinib—in people with previously untreated follicular lymphoma. The goal is to find the safest dose and see how well patients tolerate the treatment. About 33 participants with stage II…

This phase II trial tests a drug called copanlisib in 35 patients with advanced cancers that have a specific mutation in the PTEN gene. The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or slow the disease. The study is small …

This phase II trial is studying a combination of chemotherapy (Hyper-CVAD) and the targeted drug dasatinib, with or without a donor stem cell transplant, in 97 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see how well this approa…

This study tests whether the immunotherapy drug nivolumab can wipe out any leftover leukemia cells and prevent the cancer from returning in people with acute myeloid leukemia (AML) who are already in remission after chemotherapy. The trial enrolled 82 adults whose AML had respond…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, in people with anal cancer that has spread and not responded to prior treatment. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 143 adults with advanced squamous cell carcinoma o…

This study tests whether a combination of two targeted drugs, trastuzumab and pertuzumab, can shrink or slow the growth of certain cancers that have a specific gene change called HER2 amplification. The cancers studied are not breast, stomach, or colorectal types. About 35 adults…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps prevent colon cancer from coming back in patients with stage II colon cancer at high risk for recurrence. Over 2,400 participants who had surgery were randomly assigned to receive eithe…

This study tested whether taking lenalidomide after a stem cell transplant helps keep multiple myeloma from coming back. About 460 patients who had a transplant received either lenalidomide or a placebo. The goal was to see if the drug could delay cancer progression. While lenali…

This study tested two drugs, osimertinib and bevacizumab, in people with a specific type of lung cancer (EGFR mutation-positive) that had spread to the brain. The goal was to see if adding bevacizumab to osimertinib could help control the cancer longer. The trial enrolled 5 parti…

This early-phase study tests two experimental drugs, sapanisertib and telaglenastat, in people with advanced non-small cell lung cancer that has spread to the brain or other areas. The main goal is to find the safest dose and see if the combination can shrink tumors or slow the d…

This study compares the drug lenalidomide to simply watching and waiting in people with high-risk smoldering multiple myeloma, a condition that may turn into active cancer. The goal is to see if lenalidomide can delay progression and improve outcomes. About 226 participants were …

This phase 2 trial studies a combination of two immunotherapy drugs—talimogene laherparepvec (T-VEC) and pembrolizumab—in 43 adults with advanced melanoma that has worsened despite prior anti-PD1/L1 therapy. T-VEC is a modified virus that infects and kills cancer cells while also…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This early-stage study tested the safety and best dose of vorinostat when given with the chemotherapy drug temozolomide in 83 adults with aggressive brain tumors called malignant gliomas. The goal was to see if adding vorinostat could make the tumor cells more sensitive to chemot…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a certain type of leukemia (BCR-ABL-negative B-ALL) live longer and stay cancer-free longer. About 488 newly diagnosed patients took part. The goal is to see if the comb…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…

This early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…

This study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could switch to a thalidomide-base…

This study tests whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers, such as cervical, anal, and throat cancers. About 51 adults with cancers that have spread or not responded to standard treatments will receive the drugs for …

This study tests a combination of two drugs—cetuximab and interleukin-12—in people with head and neck cancer that has returned, spread, or cannot be removed by surgery. The goal is to find the safest dose of interleukin-12 and see if the pair can shrink tumors. About 23 adults wi…

This early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…

This early-stage trial tests a new drug (CB-839 HCl) combined with two standard treatments for multiple myeloma that has returned or is not responding. The main goal is to find the safest dose and see how well the combination works. About 36 adults with relapsed or refractory mul…

This study tests two drug combinations (belinostat plus either guadecitabine or ASTX727) in 19 adults with a rare bone cancer called chondrosarcoma that has spread or cannot be removed surgically. The goal is to see if the drugs can shrink tumors or stop them from growing. Partic…

This study tests a drug called GSK2636771 in people with advanced cancers that have a specific genetic change (PTEN mutation or deletion). The drug blocks a protein that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from grow…

This early-stage trial tests a drug called TAK-243 in about 42 adults whose acute myeloid leukemia or myelodysplastic syndrome has come back or stopped responding to standard therapy. The main goal is to find the safest dose and understand side effects. TAK-243 works by blocking …

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests the drug avelumab in people with thymoma or thymic carcinoma that came back after platinum-based chemotherapy. Avelumab helps the immune system fight cancer. The goal is to see if it is safe and can shrink or slow tumor growth. About 56 adults will receive the dr…

This study tested whether adding veliparib (a PARP inhibitor) to the chemotherapy drug temozolomide helps people with small cell lung cancer that has come back or stopped responding to treatment. About 97 participants received either the drug combo or a placebo with temozolomide.…

This study tests a drug called copanlisib in people whose cancers have a specific genetic mutation (PIK3CA). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with advanced…

This study tests a combination of three drugs (copanlisib, nivolumab, and ipilimumab) in adults with advanced solid tumors that have specific gene changes (PIK3CA or PTEN). The goal is to find the best dose and see if the combo is safe and shrinks tumors. About 54 people will tak…

This study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …

This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help …

This study tests a new combination of drugs (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this new combo to the current standard treatment. The goal is to see if the new approach leads to better cancer control. About 70 participants will take …

This study tests whether adding an experimental drug (M6620) to standard chemotherapy (gemcitabine) works better than gemcitabine alone for women with ovarian, peritoneal, or fallopian tube cancer that has returned and no longer responds to platinum-based treatments. About 70 par…

This study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either tram…

This early-stage trial tested two drugs, adavosertib and olaparib, given one after the other in 13 people with advanced solid tumors that have specific genetic changes. The goal was to find the best dose and check for side effects, while also seeing if the combination could shrin…

This study tests a drug called trametinib in children with a rare blood cancer (juvenile myelomonocytic leukemia) that has returned or not responded to treatment. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if it can shrink or contro…

This early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with limited stage small cell lung cancer live longer. About 544 participants will receive either chemoradiation alone or chemoradiation plus atezolizumab. The goal is to s…

This phase II trial tests pembrolizumab, an immunotherapy drug, in 57 patients with desmoplastic melanoma, a rare skin cancer. The drug helps the immune system attack cancer cells. The study includes patients whose tumors can be surgically removed (cohort A) and those whose canno…

This phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.

This early-stage trial tests whether adding the immunotherapy drug ipilimumab to the chemotherapy drug decitabine is safe and tolerable for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has come back or stopped responding to treatment. About 54 p…

This phase 2 trial tests the drug crizotinib in 44 adults with advanced or treatment-resistant solid tumors, lymphoma, or multiple myeloma that have a specific genetic change called MET amplification. Crizotinib is a pill that blocks enzymes cancer cells need to grow. The main go…

This early-stage trial tests a combination of three drugs—lenalidomide, dinutuximab, and isotretinoin—in children whose neuroblastoma has not responded to treatment or has come back. The main goal is to find the safest dose of lenalidomide when used with the other drugs. Research…

This phase II trial tests whether adding the immunotherapy drug nivolumab to the chemotherapy paclitaxel helps shrink tumors in people with angiosarcoma who haven't had taxane drugs before. For those who have already received taxanes, the trial tests a combination of nivolumab an…

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to the bones. Olaparib blocks a protein that cancer cells use to repair themselves, while radium-223 delivers radiation directly to bone tumors. Th…

This early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. The study includes 15 people with lung cancer that has spread to the brain. The goal is to find out if this combination is safe enough t…

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This phase 2 trial tests the drug vismodegib in 34 people with advanced solid tumors, lymphoma, or multiple myeloma that have specific mutations in the SMO or PTCH1 genes. Vismodegib blocks a protein that can fuel cancer growth. The study aims to see if the drug can shrink or sta…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This phase II trial tests whether adding talazoparib to atezolizumab maintenance therapy works better than atezolizumab alone for people with a specific genetic marker (SLFN11-positive) and extensive-stage small cell lung cancer. About 100 participants will receive either the com…

This phase II study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) combined with targeted radiation in people with microsatellite stable (MSS) metastatic colorectal cancer, a type that typically doesn't respond to immunotherapy. The trial was withdrawn befor…

This phase III trial is testing whether adding cabozantinib (a targeted therapy) to avelumab (an immunotherapy) as maintenance treatment works better than avelumab alone for people with metastatic urothelial cancer that has not progressed after initial chemotherapy. About 654 par…

This phase 2 trial tests the drug ivosidenib in children and young adults (ages 1 to 21) whose solid tumors, lymphomas, or related cancers have come back or not responded to treatment and carry an IDH1 mutation. The study enrolls only 3 participants and measures how many patients…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase trial tests a drug called birinapant together with a second course of targeted radiation for people whose head and neck cancer has come back in the same area. The drug works by blocking a protein that helps cancer cells survive. The main goals are to find the saf…

This phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …

This study was designed to see if the immunotherapy drugs nivolumab (with or without ipilimumab) could help people with colorectal or gastroesophageal cancer avoid or delay surgery. The trial planned to enroll adults with stage I-III cancers, but it was withdrawn before any parti…

This phase 3 trial tests whether taking erlotinib (Tarceva) after surgery helps people with a specific type of lung cancer (EGFR-mutant non-small cell) live longer without the cancer coming back. About 390 participants who had their tumor completely removed are randomly assigned …

This phase 2 trial tests the immunotherapy drug atezolizumab, alone or with bevacizumab, in 63 people with advanced alveolar soft part sarcoma that cannot be surgically removed. Atezolizumab helps the immune system attack cancer cells, while bevacizumab cuts off the tumor's blood…

This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…

This early-phase trial is testing a combination of the immunotherapy drug atezolizumab, two chemotherapy drugs (gemcitabine and oxaliplatin), and the targeted antibody rituximab in 24 patients with transformed diffuse large B-cell lymphoma that has come back or stopped responding…

This phase 2 trial tested adding bevacizumab to standard chemotherapy and radiation for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients. The goal was to see if the combination could improve tumor c…

This phase 2 trial tests a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—in 17 people with metastatic poorly differentiated neuroendocrine carcinomas. Cabozantinib blocks enzymes that help cancer grow, while nivolumab and ipilimumab are immunotherapies that b…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This study tests a drug called elimusertib in children and young adults (ages 1 to 30) whose solid tumors have returned or not responded to treatment. The drug works by blocking an enzyme that cancer cells need to grow. The trial aims to find the safest dose and see if the drug c…

This early-phase trial is testing whether a gel form of the drug endoxifen can be safely applied to the skin in women scheduled for breast surgery. The study includes 32 women with various stages of breast cancer or high genetic risk. Researchers are checking for skin reactions a…

This early-phase trial is testing whether combining the targeted drug trastuzumab deruxtecan (DS-8201a) with an experimental pill called ceralasertib can safely treat advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the safest dose in 51 pa…

This phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This early-phase trial is testing whether adding the drug lenalidomide to standard chemotherapy (EPOCH) is safe and effective for adults with a rare, aggressive blood cancer called adult T-cell leukemia-lymphoma (ATLL) linked to HTLV-1 infection. About 30 participants will receiv…

This early-phase trial tests the safety and best dose of combining ibrutinib and palbociclib in 28 patients with mantle cell lymphoma that has come back after treatment. Both drugs block enzymes that help cancer cells grow. The study aims to find a dose that is safe enough to tes…

This study tested two different doses of imatinib and another drug called dasatinib in 406 people with newly diagnosed chronic phase chronic myeloid leukemia (CML). The goal was to see which treatment best reduced cancer cells in the blood. Results showed that both drugs can effe…

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrin…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific genetic change (SPOP mutation) and has stopped responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 c…

This study compares a targeted drug called selumetinib to standard chemotherapy (carboplatin/vincristine) in children aged 2 to 21 with neurofibromatosis type 1 (NF1) and low-grade glioma, a type of brain tumor. The goal is to see if selumetinib works as well or better at control…

This study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…

This study tests a combination of two drugs, eribulin and copanlisib, in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combo can slow tumor growth better than eribulin alone. About 24 …

This large phase 3 study tests whether adding the drug blinatumomab to standard chemotherapy can improve outcomes for children and young adults with newly diagnosed B-cell acute lymphoblastic leukemia or lymphoma, including those with Down syndrome. The trial enrolls over 6,700 p…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…

This study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better slows …

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial studies whether adding the drug copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) is safe and effective for people with hormone receptor-positive, HER2-negative breast cancer that has spread. About 24 participants will receive either…

This early-phase study tests a new drug (BAY 1895344) combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, including small cell lung cancer, neuroendocrine cancer, and pancreatic cancer. The goal is to find the safest dose and check …

This study compares a targeted immune therapy called blinatumomab to standard chemotherapy in 669 children and young adults (ages 1-30) whose B-cell acute lymphoblastic leukemia has returned after initial treatment. The goal is to see if blinatumomab can keep the cancer away long…

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This early-stage trial tests a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with a rare blood disease called light chain amyloidosis that has returned or not responded to prior treatment. The goal is to find the safest dose and check for side …

This study tests a combination of drugs (berzosertib, carboplatin, gemcitabine, and pembrolizumab) in people with advanced squamous non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combo helps control the cancer longer than standard tre…

This early-phase trial tests the safety and best dose of adding ipatasertib to standard chemotherapy (paclitaxel and carboplatin) for people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. About 25 participants will receive the combination before surge…

This study tests whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel) can shrink or slow the growth of advanced solid tumors that have specific changes in the PTEN or AKT genes. About 33 adults whose cancer has spread or cannot be removed by surgery …

This study tests a combination of two drugs (peposertib and avelumab) plus a special type of radiation for people with advanced solid tumors or bile duct cancers that have spread. The goal is to find the safest dose and see if the treatment can shrink tumors that weren't directly…

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usu…

This study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard radiation therapy can better prevent endometrial cancer from coming back. It includes 164 people with newly diagnosed, early-stage cancer that has a specific genetic feature (dMMR). The goal is to s…

This study tests whether adding an experimental drug (CMP-001) to the immunotherapy pembrolizumab can better shrink melanoma tumors before surgery and help prevent them from coming back. About 60 adults with stage III or recurrent melanoma that can be surgically removed will rece…

This study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…

This study tests a new three-drug combination (tazemetostat, dabrafenib, and trametinib) in people with advanced BRAF-mutated melanoma whose cancer worsened despite prior BRAF/MEK inhibitor therapy. The goal is to find the best dose and see if the combo can slow tumor growth. Abo…

This study tests whether giving the immunotherapy drug pembrolizumab both before and after surgery works better than after surgery alone for people with high-risk stage III-IV melanoma. About 313 participants will receive pembrolizumab either before and after surgery or only afte…

This study tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 adults with this rare skin cancer will receive either nivolumab alone or nivolumab plus cabozantinib. The goal is to see which app…

This study is for people with aggressive B-cell lymphomas that have returned or not responded to standard treatments. It tests whether adding varlilumab to nivolumab (both drugs that help the immune system fight cancer) works better than nivolumab alone. About 54 participants wil…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This study tests whether adding an immunotherapy drug (atezolizumab) to standard radiation therapy helps people with early-stage non-small cell lung cancer live longer. About 415 participants with stage I-IIA lung cancer will receive either radiation alone or radiation plus atezo…

This study tests whether adding veliparib to the standard chemotherapy drug temozolomide helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The trial includes 447 patients whose tumors have a specific genetic change (MGMT promoter hypermethylation).…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had all visible tumors surgically removed. About 129 adults with advanced kidney cancer that spread to other parts of the body but showed no signs of disease after s…

This study is for people with a rare, aggressive brain tumor called high-grade meningioma that has come back after radiation. It tests whether adding immunotherapy drugs (nivolumab with or without ipilimumab) to precise, high-dose radiation can help shrink the tumor or slow its g…

This study is for people aged 65 and older who have chronic lymphocytic leukemia (CLL) that hasn't been treated yet. It compares three treatment plans: a standard chemo-immunotherapy (bendamustine plus rituximab), a targeted therapy plus immunotherapy (ibrutinib plus rituximab), …

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This early-phase trial tests a combination of three drugs—tazemetostat, topotecan, and pembrolizumab—in adults with small cell lung cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combo can shrink or stabilize the cancer. About…

This early-stage trial tests the safety of combining two drugs (olaparib and durvalumab) with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple approach can help control tumor growth. About 18…

This study tests whether adding the drug ibrutinib to standard chemotherapy before and after a stem cell transplant helps people with a specific type of lymphoma (activated B-cell diffuse large B-cell lymphoma) that has returned or not responded to treatment. About 94 participant…

This study tests whether adding the immunotherapy drug nivolumab after standard chemoradiation helps prevent anal cancer from coming back in patients with high-risk stage II-IIIB disease. About 344 adults with squamous cell carcinoma of the anus are enrolled. Nivolumab boosts the…

This study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…

This study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 different rare tumor types. The goal was to see if these drugs could shrink tumors and help control the cancer. The trial is no longer recruiting, and results are bein…

This study tests whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug gemcitabine can better control bladder cancer that has not responded to standard BCG treatment. The trial involves 161 adults with a specific type of non-muscle invasive bladder cancer. …

This study tests two treatment plans for people with advanced non-squamous non-small cell lung cancer. One group gets immunotherapy (pembrolizumab) alone first, then chemo plus or minus immunotherapy later. The other group gets immunotherapy plus chemo from the start, followed by…

This study tests a combination of two drugs, trametinib and navitoclax, in people with advanced solid tumors that have specific mutations in the KRAS or NRAS genes. The goal is to find the safest dose and see if the drugs can shrink tumors or slow their growth. About 96 participa…

This study tests a drug called palbociclib in 40 adults with advanced cancers that have specific genetic changes (CCND1, 2, or 3 amplifications). The drug blocks certain proteins that help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting wors…

This study tests whether a combination of chemotherapy, a blood vessel blocker (bevacizumab), and an immunotherapy drug (atezolizumab) works better than atezolizumab alone for people with a specific genetic type of advanced colorectal cancer (dMMR/MSI-H). About 120 adults with me…

This early-phase trial tests a new drug (peposertib) combined with a radioactive therapy (lutetium 177 dotatate) for people with a type of slow-growing gut and pancreas cancer called neuroendocrine tumors. The goal is to find the safest dose and see if the combination shrinks tum…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This early-phase study tests a new drug called uproleselan combined with two standard chemotherapy drugs for children and teens with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. The drug works by blocking a protein that helps c…

This study tests a combination of three drugs (entinostat, PDS01ADC, and bintrafusp alfa) in adults with advanced cancers linked to HPV or certain colon cancers that haven't responded to standard treatments. The goal is to find a safe dose and see if the treatment can shrink tumo…

This study tested the drug trametinib in 35 adults with advanced cancers that have specific BRAF gene changes (mutations or fusions). Trametinib blocks certain proteins that help cancer cells grow. The goal was to see if the drug could shrink tumors or stop them from growing. Par…

This early-phase study tests a new drug called navtemadlin (KRT-232) combined with standard chemotherapy (cytarabine and idarubicin) in adults with newly diagnosed acute myeloid leukemia (AML). The goal is to find the safest dose and see how well the combination works. About 24 p…

This study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…

This study tests whether combining the drug lenalidomide with a vaccine can help people with early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have high-risk genetic features. Lenalidomide aims to boost the immune system and stop cancer growth…

This early-stage trial tests a combination of two drugs, duvelisib and nivolumab, in adults with advanced mycosis fungoides or Sézary syndrome (types of skin lymphoma). The goal is to find the safest and most effective dose and see if the combo works better than standard treatmen…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent colon cancer from returning after surgery. It includes 712 people with stage III colon cancer that has a specific DNA repair problem (dMMR). The main goal is to see if th…

This study tests a combination of three drugs (darolutamide, leuprolide acetate, and exemestane) in 37 people whose ovarian granulosa cell tumor has returned. The drugs work together to block hormones that may fuel tumor growth. The goal is to shrink or stabilize the tumor and pr…

This study tests whether adding the experimental drug veliparib to standard chemotherapy (topotecan and carboplatin) works better than chemo alone for people with advanced myeloproliferative disorders or certain leukemias. About 25 adults with these blood cancers that have spread…

This study tests whether adding a radioactive drug (radium-223) to standard treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 participants will receive either the combination or cabozantinib alone. The goal is to see if the …

This study tests whether a new drug combination (bevacizumab plus anetumab ravtansine) works better than standard chemotherapy (bevacizumab plus paclitaxel) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatme…

This early-phase trial tests a new treatment for people with B-cell cancers (like leukemia or lymphoma) that haven't improved with standard therapies. The approach uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main…

This study tests a drug called tipifarnib in children and young adults (ages 1 to 21) whose cancers have a specific change in the HRAS gene. The cancers are advanced or have come back after treatment. The goal is to see if tipifarnib can shrink tumors or stop them from growing. A…

This study tests a drug called erdafitinib in children and young adults (ages 1 to 21) whose cancers have come back or are not responding to treatment and have specific changes in FGFR genes. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see …

This study tests whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemo. About 582 women took part.…

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…

This early-phase study tests a new three-drug combination for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The treatment includes a targeted radiation antibody (lintuzumab-Ac-225) plus two oral drugs (venetoclax and ASTX-727).…

This large study looked at over 10,000 women with early-stage, hormone-sensitive breast cancer that had not spread to lymph nodes. It used a genetic test called Oncotype DX to see who could safely skip chemotherapy and just take hormone therapy. The goal was to find the best trea…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot have high-dose therapy. The goal is to see which combination better delays cance…

This study tests a drug called selpercatinib in children and young adults (ages 1 to 21) whose cancers have a specific RET gene change. The goal is to see if the drug can shrink tumors or stop them from growing. Participants have advanced solid tumors, lymphomas, or related disor…

This study tests whether adding venetoclax to ASTX727 (a two-in-one pill) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will be randomly assigned to one of the two trea…

This study tests a drug called AZD1775 in people whose advanced cancers have a BRCA1 or BRCA2 gene mutation. The drug blocks a protein (WEE1) that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with various adva…

This early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …

This early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…

This study aimed to test a combination of two immunotherapy drugs (nivolumab and ipilimumab) in children, adolescents, and young adults with cancers that returned or didn't respond to treatment and had many genetic mutations. The goal was to see if the drugs could shrink or stabi…

This early-phase trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy before and after surgery is safe and feasible for people with resectable malignant pleural mesothelioma. 28 participants with stage I-III disease received the drug combinatio…

This early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…

This study tests a two-step treatment for people with stage II or III non-small cell lung cancer who are not healthy enough for surgery. First, they receive a shorter, higher-dose course of radiation. Then they get an immunotherapy drug called atezolizumab to help their immune sy…

This study tests two drugs, selumetinib and vinblastine, alone or together, in children and young adults (ages 2-25) with a type of brain cancer called low-grade glioma that has come back or not responded to treatment. The goal is to see if adding vinblastine to selumetinib works…

This early-stage trial tests a new drug (M3814) combined with three chemotherapy drugs for people whose acute myeloid leukemia has returned or not responded to standard treatment. The main goal is to find the best dose and check for side effects. About 48 adults will take part.

This study compares a standard chemotherapy drug (azacitidine) alone versus combined with either lenalidomide or vorinostat for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if adding another drug improves re…

This study is for people with a type of slow-growing lymphoma (grades 1-3a) that has returned or not responded to earlier treatment. It tests whether adding other drugs to a standard immunotherapy (obinutuzumab) can improve results. About 73 adults will receive different treatmen…

This study tests whether a combination of two oral medications (ASTX727 and venetoclax) can work as well as standard intravenous chemotherapy for younger adults (ages 18-65) with a high-risk form of acute myeloid leukemia (AML). The goal is to find a safe, effective dose and see …

This study tests whether adding berzosertib to standard chemotherapy (topotecan) helps people with relapsed small cell lung cancer live longer without their cancer growing. About 104 participants will receive either the combination or topotecan alone. The goal is to see if blocki…

This study tested the drug trametinib in 4 people with advanced cancers that have GNAQ or GNA11 gene mutations. Trametinib blocks certain proteins that help these cancers grow. The goal was to see if the drug could shrink tumors or stop them from getting worse.

This study tests the drug sunitinib in people with advanced cancers that have a specific change in the cKIT gene. Sunitinib works by blocking signals that make cancer cells grow. The trial includes about 10 adults with lymphoma, solid tumors, or multiple myeloma that have not res…

This early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…

This phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal was…

This study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…

This phase III trial tested two different sequences of treatments for people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib),…

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This study tests a mix of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE (which delivers chemotherapy beads to the liver) in people with advanced liver or bile duct cancer. The goal is to see if this combination can stop the cancer from growing f…

This study looks at whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can help control blood cancers like leukemia and lymphoma with fewer side effects. About 105 people aged 15-65 with high-risk blood cancers will receive a transplant from a …

This study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer before and after surgery. About 278 adults with stage II to IVA cancer will take part. The…

This study tests a drug called ado-trastuzumab emtansine in people whose cancers have too many HER2 receptors (HER2 amplification), but not breast or stomach cancers. The drug combines an antibody that targets HER2 with a chemotherapy agent to kill cancer cells. Researchers want …

This early-stage trial tested the safety and best dose of two drugs—cyclophosphamide and veliparib—given together to people with HER2-negative breast cancer that has spread or cannot be removed by surgery. The goal was to find the right dose for future studies and see if the comb…

This study tests whether adding a drug called triapine to the standard radioactive treatment Lutathera works better than Lutathera alone for people with advanced neuroendocrine tumors that have spread. About 94 participants will receive either the combo or standard therapy. The g…

This study tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma, a type of blood cancer, in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over up to 13 cycles. The goal is to see how many achieve …

This early-phase trial tested the safety of combining two drugs, nivolumab and cabozantinib, in 8 people with HIV who also have advanced solid tumors. The goal was to see if the combination is safe and can shrink or stabilize the cancer. The study focused on finding the right dos…

This study tests whether adding the immunotherapy drug durvalumab to standard chemoradiation, and continuing it afterward, helps people with stage III lung cancer that cannot be surgically removed live longer and keep the cancer from coming back. About 660 adults with newly diagn…

This study tests two immunotherapy drugs, atezolizumab and tiragolumab, in people with rare solid tumors that have spread or not responded to standard treatments. The goal is to see if the combination can shrink tumors and boost the immune system's attack on cancer. Researchers w…

This study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…

This study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…

This study compares two chemotherapy regimens (carboplatin+paclitaxel vs oxaliplatin+capecitabine), each with or without the targeted drug bevacizumab, as first treatment for mucinous ovarian or fallopian tube cancer. About 50 people with newly diagnosed or recurrent disease took…

This study is for people with non-small cell lung cancer who have had chemotherapy and surgery. It tests whether adding a drug called AZD6738 to the immunotherapy drug durvalumab can help keep the cancer from coming back longer than durvalumab alone. About 630 adults with stage I…

This study tests whether adding the immunotherapy drug cemiplimab to standard surgery (with or without radiation) helps people with advanced squamous cell skin cancer that can be surgically removed. About 420 adults with stage III or IV disease will be randomly assigned to receiv…

This study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…

This study tests whether the drug trametinib can make radioactive iodine treatment more effective for people with advanced thyroid cancer that has stopped responding to standard therapy. About 34 adults with certain genetic types of thyroid cancer will receive trametinib followed…

This study tests a drug called afatinib in 40 adults with advanced cancers that have a specific genetic change called a HER2 mutation. Afatinib works by blocking the HER2 protein, which may help stop cancer cells from growing. The goal is to see if the drug can shrink tumors or s…

This early-stage trial tests a new drug called CA-4948 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink …

This early-phase trial tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that had a specific BRAF mutation and could not be removed by surgery. The main goal was to find the safest dose of lapatinib when given with dab…

This early-phase study tests a combination of five drugs (VIPOR) in 14 adults with aggressive B-cell lymphoma that has spread to the brain or spinal cord. The main goal is to see if the treatment is safe enough for patients to complete at least two 21-day cycles without serious s…

This early-stage trial aimed to test a new drug called CB-5339 in people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The drug works by blocking certain enzymes that cancer cells need to grow. However, the study was withdrawn before …

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This early-phase study tested an oral drug called triapine added to standard chemotherapy (cisplatin) and radiation for people with advanced cervical or vaginal cancer. The main goals were to find the safest dose and check how well the body absorbs the drug. Twenty-one participan…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…

This study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…

This study tests a drug called MLN0128 (TAK-228) in 49 adults with advanced cancers that have TSC1 or TSC2 mutations. The drug works by blocking enzymes that help cancer cells grow. Researchers will check if tumors shrink or stop growing, and track how long patients live or stay …

This study tested a drug called atezolizumab in 27 people with rare cancers of the bone (chondrosarcoma) or soft tissue (clear cell sarcoma) that could not be removed by surgery or had spread. The drug helps the body's immune system attack cancer cells. The main goal was to see i…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is …

This early-phase study tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation for people with advanced head and neck cancer that has spread to nearby tissues or lymph nodes. The main goal is to find the safest dose and check for side…

This study tests a drug called ibrutinib in people with stage IV melanoma (skin cancer that has spread) that did not get better with other treatments. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal is to see if the drug can shrink tumors…

This study tests an HPV vaccine (PRGN-2009) alone or combined with a drug called M7824 in people with HPV-positive cancers that have spread or come back. The goal is to find a safe dose and see if the combination boosts the immune system to fight the cancer better. Participants r…

This study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…

This study tested whether adding lenalidomide to standard chemoimmunotherapy (R-CHOP) helps people with newly diagnosed, advanced diffuse large B-cell lymphoma. About 349 participants received either R-CHOP alone or R-CHOP plus lenalidomide. The goal was to see if the combination…

This study is for adults aged 18 to 75 with a specific type of leukemia called BCR-ABL-positive acute lymphoblastic leukemia (ALL). It compares the usual treatment (steroids, a targeted drug, and chemotherapy) with the same treatment plus an extra drug called blinatumomab. The go…

This study tests a drug called selumetinib in children and young adults with low grade glioma that has come back or not responded to other treatments. The drug works by blocking certain enzymes that help tumor cells grow. The goal is to find the best dose and see if it can shrink…

This study tests whether adding an experimental drug (M6620) to standard chemotherapy can better shrink tumors or slow the disease in men with advanced prostate cancer that no longer responds to hormone therapy. About 73 participants will receive either M6620 plus carboplatin or …

This phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This study tests a drug called trametinib in 50 patients whose cancers have a specific genetic change called an NF1 mutation. The drug blocks certain proteins that help cancer cells grow. The goal is to see if trametinib can shrink tumors or stop them from growing.

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This study tests a drug called ipatasertib in 35 adults with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an AKT mutation. The drug works by blocking a protein that helps cancer cells grow. The main goal is to see if the tumors shrin…

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, a fast-growing brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. A…

This study tested two different doses of the immunotherapy drug ipilimumab, either alone or combined with high-dose interferon, in 88 people with advanced melanoma that could not be surgically removed. The goal was to see if the combination could delay cancer growth better than i…

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…

This early-stage study is testing a combination of three drugs (alisertib, bortezomib, and rituximab) in about 24 people with mantle cell or low-grade non-Hodgkin lymphoma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the…

This study tests an experimental pill called alvelestat in people who developed a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The goal is to find a safe dose that blocks a harmful enzyme and improves lung function. About 14 adults with…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 adults with advanced cancer that has spread will receive the drugs alone…

This phase 3 trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with muscle-invasive bladder cancer live longer without their cancer returning or needing bladder removal. About 475 adults with localized disease are participating…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the disease getting worse. About 800 participants with stage III, IV, or recur…

This study tests a combination of two drugs, sacituzumab govitecan and berzosertib, in adults with small cell lung cancer or cancers that have stopped responding to PARP inhibitors. The goal is to find a safe dose and see if the combo can shrink tumors. Participants receive the d…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy works better than chemotherapy alone for people with anal cancer that has spread. About 205 adults with inoperable or metastatic anal cancer will receive either the combination or standard t…

This study tests whether adding two targeted drugs (atezolizumab and bevacizumab) to standard chemotherapy helps people with a rare, advanced liver cancer live longer without their disease getting worse. About 88 adults with cancer that cannot be surgically removed will be random…

This study tests whether adding a targeted drug called ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. The trial includes 312 participants and aims to see if the combination improves survival without the cancer growing back. The…

This study tests a pill called osimertinib in people with advanced cancers (like lymphoma or solid tumors) that have a specific genetic change called an EGFR mutation. The drug blocks a faulty protein that helps cancer grow. The goal is to see if the drug can shrink or slow the c…

This study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …

This study tested a new drug called veliparib, given with radiation and chemotherapy, for children and young adults with a fast-growing brain tumor (high-grade glioma). The goal was to see if adding veliparib helps keep the cancer from coming back longer than standard treatment. …

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…

This study tested whether adding the drug entinostat to standard hormone therapy (exemestane) helps people with advanced hormone receptor-positive breast cancer live longer without their cancer growing. About 600 adults with breast cancer that had spread or come back took part. T…

This early-phase trial tested a combination of a BET inhibitor (ZEN003694) with immunotherapy drugs (nivolumab with or without ipilimumab) in people with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see if the combo…

This study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. Olaparib blocks a protein that helps cancer cells repair themselves, while temozolomide damages cancer cell DNA. The go…

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take the drug twice daily and are monitored …

This study tests whether adding an immunotherapy drug (tremelimumab) to a targeted therapy (olaparib) helps control recurrent ovarian, fallopian tube, or peritoneal cancer better than olaparib alone. About 61 adults with platinum-sensitive cancer are participating. The goal is to…

This study tests a drug called copanlisib in 22 adults with various cancers that have lost a protein called PTEN. The drug works by blocking enzymes that help cancer cells grow and survive. The main goal is to see if the drug can shrink tumors or stop them from growing for at lea…

This study tests a drug called telaglenastat (CB-839) in about 54 adults with advanced solid tumors or malignant peripheral nerve sheath tumors that have specific genetic changes (NF1, KEAP1/NRF2, or LKB1 mutations). The drug works by blocking an enzyme that cancer cells need to …

This study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…

This study tests a drug called AZD5363 in 35 adults whose cancers have a specific genetic change (AKT mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. Participants have advanced solid tum…

This study tests whether combining two drugs, talazoparib and temozolomide, can shrink or stop the growth of rare cancers that have spread. The drugs work by damaging cancer cell DNA and blocking its repair. The trial includes 14 adults with advanced rare solid tumors, like pheoc…

This early-phase trial tests the safety and best dose of the drug trametinib when given with or without whole-brain radiation for people with cancer that has spread to the brain. Trametinib blocks certain enzymes that help cancer cells grow, and radiation uses high-energy X-rays …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to see if the combination helps shrink tumors and allows patie…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial includes 37 adults and aims to find t…

This study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…

This study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…

This study compared pembrolizumab (Keytruda) to the usual treatments (high-dose interferon or ipilimumab) in over 1,300 people with high-risk melanoma that was surgically removed. The goal was to see if pembrolizumab could better prevent the cancer from coming back or spreading. …

This study tested the drug crizotinib in 5 patients with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink or stop the growth of these tumors. The approach uses a targeted therapy to block a protein that he…

This phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.

This study tests a combination of six drugs (TEDDI-R) for people whose aggressive B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this mix can control the cancer better than current treatments. About 48 adults with relapsed or refractory disease will…

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in 59 people with advanced solid tumors, including melanoma, colorectal, ovarian, and k…

This study tests whether adding iadademstat to the drug ASTX727 works better than ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults whose cancer has progressed to a more aggressive phase will be randomly assigned…

This early-stage study tests a mix of six drugs (called ViPOR-P) in adults with B-cell lymphomas that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 34 participants will take pills and receive infusions o…

This study tests two drugs that lower or block male hormones to slow or shrink a rare type of salivary gland cancer that has spread or come back. About 21 people whose cancer has male hormone receptors and who have not had hormone therapy before will take darolutamide pills and g…

This study tests a pill called erdafitinib in 35 adults whose cancers have specific FGFR gene mutations or fusions. The drug blocks a faulty protein that helps cancer grow, potentially shrinking tumors or slowing the disease. It is a phase 2 trial for advanced solid tumors that h…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This study tests a drug called ibrutinib in 44 people whose hairy cell leukemia has come back after treatment. Ibrutinib works by blocking a protein that cancer cells need to grow. The main goal is to see how many patients have their cancer shrink or disappear within 32 weeks.

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This study compares three different drug combinations in 444 people with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum chemotherapy. The drugs include a standard chemotherapy (pegylated liposomal doxorubicin) plus one or two immune-boosting o…

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…

This study tested two drugs, erlotinib and cabozantinib, given alone or together in 125 people with advanced non-small cell lung cancer that had already been treated. The goal was to see if the combination worked better than either drug alone at slowing cancer growth. Participant…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This large phase 3 study tested whether the immunotherapy drug ipilimumab works better than high-dose interferon alfa-2b at preventing melanoma from coming back after surgery. Over 1,600 patients with high-risk stage III or IV melanoma that had been completely removed took part. …

This study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.

This early-stage trial tests a new drug called MEDI-570 in people with certain types of T-cell lymphoma that have returned or not responded to prior treatments. The main goals are to find the safest dose and understand side effects. The drug works by helping the immune system att…

This study tests a new drug, PEN-866, combined with two standard chemotherapy drugs (vincristine and temozolomide) for adolescents and young adults aged 12-39 whose solid tumors, including Ewing sarcoma and rhabdomyosarcoma, have returned or not responded to standard treatments. …

This study tests a drug called crizotinib in people with advanced cancers that have a specific genetic change (MET exon 14 deletion). The drug blocks enzymes that help cancer grow. About 20 participants will receive the treatment to see if their tumors shrink or stop growing.

This study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …

This early-phase study tests the safety of the immunotherapy drug atezolizumab given after a patient's own immune cells have been modified and infused back (adoptive cell transfer). It includes 40 adults with advanced blood or solid cancers that no longer respond to standard trea…

This study tests two oral drugs, mirdametinib and sirolimus, together in people with a specific genetic form of multiple myeloma that has returned or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink or control the cancer. About 54 …

This early-phase study tested two experimental drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and check for side effects. The drugs work by blocking blood vessel gr…

This study tested a drug called ibrutinib in 41 people with follicular lymphoma that returned or didn't respond to prior treatment. Ibrutinib works by blocking certain enzymes that cancer cells need to grow. The main goal was to see how many patients had their tumors shrink or di…

This study looks at whether adding an immunotherapy drug (nivolumab) to the usual two-drug treatment can better shrink tumors in people with a specific type of advanced colorectal cancer (BRAF-mutated, microsatellite stable). About 86 adults whose cancer has spread or can't be re…

This study tests whether a stem cell transplant from a matched sibling, unrelated donor, or half-matched parent can fix the immune system in people with DOCK8 deficiency, a genetic condition that causes severe infections and cancer. Participants aged 4 to 35 receive chemotherapy …

This study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…

This early-stage study tests a combination of targeted therapy (ibrutinib) and chemotherapy (TEDDI-R) in people with primary CNS lymphoma, a rare brain cancer. The goal is to find the safest dose and see if the treatment can control the disease. About 68 adults with relapsed or u…

This study tests a drug called taselisib in 70 people with advanced cancers that have a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing, but th…

This study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …

This study tests whether adding the targeted drug binimetinib to standard chemotherapy (FOLFOX) can shrink tumors or help people with advanced bile duct or gallbladder cancers live longer. About 66 adults whose cancers have a specific genetic change (MAPK pathway mutation) and ha…

This early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…

This phase 3 trial tests whether adding a newer drug (venetoclax) to the standard two-drug therapy (ibrutinib plus obinutuzumab) helps prevent chronic lymphocytic leukemia (CLL) from returning in older adults (65+). It also explores if patients who respond well can safely stop ta…

This study aimed to see if a person's own immune cells, modified in a lab to target specific cancer gene mutations, could prevent advanced gastrointestinal cancers from coming back after standard treatment. It was designed for people whose blood tests showed signs of remaining ca…

This large phase 3 study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) given with standard chemotherapy for people aged 12 and older with newly diagnosed, advanced-stage classical Hodgkin lymphoma. The goal is to see which combination better delays the cance…

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…

This study tests whether adding the drug temsirolimus to standard chemotherapy helps people with intermediate-risk rhabdomyosarcoma (a type of muscle cancer) live longer without the cancer growing or coming back. About 325 participants up to age 40 are randomly assigned to receiv…

This study tests whether a combination of amivantamab and hyaluronidase works as well as cetuximab for treating skin squamous cell carcinoma that has returned or spread. The trial involves 86 immunocompromised participants, such as organ transplant recipients. The goal is to comp…

This study tests a drug called MLN0128 (TAK-228) in people with advanced cancers that have a specific genetic change (mTOR mutation). The drug works by blocking enzymes that cancer cells need to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that haven't r…

This study tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent breast cancer from returning in people with triple-negative breast cancer. About 1,155 participants who still had cancer after chemo will receive either pembrolizumab or…

This early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and look at side effects. Researchers also…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants will receive either chemo alone or chemo plus uproleselan. The goal is to see i…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…

This early-phase trial is testing a combination of three drugs—lenalidomide, ibrutinib, and rituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. The main goal is to find the safest …

This early-phase study tests a new drug combination for people with advanced pancreatic cancer that has a specific marker (mesothelin). The treatment pairs a targeted chemotherapy with immunotherapy drugs and standard chemo to see if it's safe and what dose works best. About 74 a…

This study tests a drug called vorinostat in 40 people with uveal melanoma that has spread to other parts of the body. The drug works by blocking enzymes that help cancer cells grow. The main goal is to see if the drug can shrink tumors and help control the disease.

This study tested a combination of two drugs, berzosertib and irinotecan, in 17 people with advanced stomach or gastroesophageal junction cancer that had a specific genetic change (TP53 mutation) and was no longer responding to other treatments. The goal was to see if the combina…

This study tests if the immunotherapy drug nivolumab can stop or slow the growth of certain brain tumors (gliomas) that have IDH mutations. Researchers are especially interested in tumors with many genetic changes (hypermutator phenotype). The trial involves 62 adults who receive…

This phase 3 trial tests whether the immunotherapy drug pembrolizumab can prevent Merkel cell carcinoma from returning after it has been surgically removed. About 280 adults with stage I–III Merkel cell cancer will receive either pembrolizumab or standard observation. The goal is…

This early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…

This study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of aggressive brain cancer) has returned after initial treatment. About 184 partic…

This early-phase study tests a new drug (MLN0128) combined with bevacizumab in 50 adults with recurrent glioblastoma or other advanced solid tumors. The goal is to find the safest dose and understand side effects. This is not a cure, but aims to control tumor growth.

This study tests two drugs, dabrafenib and trametinib, in people with advanced cancers that have a specific genetic change called a BRAF V600 mutation. The goal is to see if these drugs can shrink tumors or stop them from growing. The trial includes 44 participants with various c…

This study tests a drug called rogaratinib in about 48 people with advanced sarcoma or a rare type of GIST that has certain genetic changes. The drug works by blocking proteins that help cancer cells grow. The goal is to see if it can shrink tumors or slow the disease, while moni…

This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdraw…

This study tests whether adding brentuximab vedotin (a drug that delivers cancer-killing substances directly to lymphoma cells) to standard chemotherapy works better than chemo alone for children and young adults with high-risk Hodgkin lymphoma. About 600 participants with stage …

This study tests whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, can lower PSA levels in men with early-stage prostate cancer. The goal is to see if this approach might allow some men to delay or avoid surgery or radiation in the futur…

This study tests a drug called ulixertinib in people with advanced cancers that have specific changes in the BRAF gene (fusions or non-V600 mutations). The drug blocks signals that tell cancer cells to grow. About 35 adults with solid tumors, lymphoma, or multiple myeloma that ha…

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This study tests whether adding a drug called sargramostim to two immunotherapy drugs (nivolumab and ipilimumab) helps people with advanced melanoma that cannot be removed by surgery. About 600 adults with stage III or IV melanoma will receive either the two-drug or three-drug co…

This large phase 3 trial studied nearly 5,000 people with breast cancer that had spread to lymph nodes or was at high risk of returning. Participants received standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) plus either bevacizumab (a drug that cuts off tumor…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps shrink tumors more than chemo alone in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus ate…

This study tests three drugs—durvalumab, olaparib, and cediranib—given together to people with advanced solid tumors or recurrent ovarian cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth. Participants take the drugs by IV or mouth daily, an…

This phase II trial tests the drug olaparib in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and whose cancer cells have a specific IDH gene change. Olaparib works by blocking enzymes that cancer cells …

This early-stage trial tests a new drug called iadademstat added to two standard chemotherapy drugs (venetoclax and azacitidine) for adults with untreated acute myeloid leukemia (AML). The main goals are to find the safest dose and check for side effects. About 45 participants wi…

This phase 2 study tests a new drug (pevonedistat) combined with two standard chemotherapies (carboplatin and paclitaxel) in 27 adults with advanced non-small cell lung cancer that has not responded to immunotherapy. The goal is to see if this combination can shrink or control th…

This early-stage trial tested a drug called adavosertib together with radiation therapy for people with advanced esophageal or stomach cancer that cannot be surgically removed. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, s…

This early-phase trial tests a treatment for people with advanced solid tumors (like colorectal, lung, or breast cancer) that have a specific genetic change called KRAS. The approach uses a person's own white blood cells, which are modified in a lab to better recognize and attack…

This study tests a combination of three drugs—dabrafenib, trametinib, and navitoclax—in people with BRAF mutant melanoma or other solid tumors that have spread or can't be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 adu…

This study tests whether adding the targeted drug olaparib to standard radiation therapy helps prevent inflammatory breast cancer from coming back. Inflammatory breast cancer is a rare and aggressive form of the disease. About 300 patients who have already had chemotherapy and su…

This study looks at whether adding radiation therapy to standard immunotherapy (with or without chemo) helps people with advanced non-small cell lung cancer that lacks the PD-L1 marker. About 427 adults with stage IIIB, IIIC, or IV cancer will be randomly assigned to get either t…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tested the drug sorafenib in 38 people with advanced gastrointestinal stromal tumor (GIST) that had stopped responding to two standard treatments, imatinib and sunitinib. Sorafenib works by blocking enzymes that help tumor cells grow and by cutting off blood supply to …

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This study tests whether a lower dose of radiation therapy combined with the immunotherapy drug nivolumab works as well as the standard radiation-plus-chemotherapy approach for people with early-stage HPV-positive throat cancer who have never smoked. About 384 participants will r…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…

This study tests a new drug called bintrafusp alfa (M7824) in people with thymoma or thymic carcinoma that returned after standard platinum chemotherapy. Nine adults with advanced, inoperable disease receive the drug every two weeks. The goal is to see if the drug shrinks tumors …

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests Radium-223 in men whose prostate cancer has returned after initial treatment, but only shows up as rising PSA levels in blood—not on standard scans. The goal is to see how the drug affects the immune system and PSA levels. Participants receive up to 6 doses of Ra…

This study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or the single dr…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study tests a combination of three drugs—ipilimumab, nivolumab, and brentuximab vedotin—in people with Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the safest doses and see how well the drugs work together to shrink or kill can…

This early-stage trial tests whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has come back or not responded to prior therapy. About 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The study…

This study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…

This study tested two drugs, olaparib and ceralasertib, in 24 people with advanced solid tumors (like bile duct cancer) that have a specific IDH gene mutation. The goal was to see if the combination could shrink or stop the growth of these hard-to-treat cancers. The trial is no l…

This early-phase trial tests a personalized cell therapy called GD2CART for children and young adults with osteosarcoma or neuroblastoma that has returned or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to recognize and attack ca…

This study tests whether adding the drug bortezomib to standard chemotherapy helps children and young adults (ages 1 to 30) with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. About 847 participants received either standard chemo alone or ch…

This early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…

This early-phase trial tested a combination of two drugs, erlotinib and irinotecan, in 60 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked for signs …

This study tests a drug called GSK2636771 in 35 adults with advanced cancers that have lost the PTEN protein. The drug blocks a protein (PI3K-beta) that helps these cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. This is a phase II t…

This early-stage trial is testing the safety and potential benefit of pembrolizumab, an immunotherapy drug, in 71 children whose brain tumors (like DIPG, high-grade gliomas, or medulloblastoma) have come back or not responded to standard treatments. The drug works by helping the …

This study tests whether adding a drug called tuvusertib (which blocks a DNA repair enzyme) to the immunotherapy avelumab can slow down advanced Merkel cell cancer that has stopped responding to standard immunotherapy. About 50 adults with this rare skin cancer will be randomly a…

This study tested the drug ensartinib in 13 children and young adults (ages 1–21) whose cancers had come back or did not respond to treatment and had specific ALK or ROS1 gene changes. The goal was to see if the drug could shrink or stop tumor growth. While the drug targets cance…

This study tests a radioactive tracer called 18F-DCFPyL to see if it can better detect prostate cancer that has spread outside the prostate or come back after treatment. About 360 men with high-risk or recurrent prostate cancer will get an injection of the tracer and then have a …

This study compares the accuracy of HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. The goal is to see if self-collection is a reliable alternative to increase screening rates and catch cervical cancer earlier. About 500 wo…

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study compares the accuracy of self-collected vaginal samples versus clinician-collected cervical samples for HPV testing in 750 people referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable alternative to traditional pelvic exams…

This study compares HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 people referred for colposcopy or cervical procedures will provide both types of samples. The goal is to see if self-collection is accurate enoug…

This study compares two types of PET scans to see which better finds prostate cancer that has spread. About 96 adults with metastatic prostate cancer will receive an experimental radiotracer (18F-DCFPyL) and a standard one (18F-NaF) on different days, then have whole-body scans. …

This study tests a special vaccine (Tri-Ad5) plus an immune booster (N-803) to see if it can prevent colon and other cancers in 186 people with Lynch syndrome, a genetic condition that raises cancer risk. The vaccine trains the immune system to recognize and destroy precancerous …

This phase II trial tests whether simvastatin, a common cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers decrease. The goal is to fi…

This large study tests whether a single dose of the HPV vaccine works as well as the standard two doses to prevent HPV infection, which causes most cervical cancers. Over 27,000 girls aged 12 to 16 are taking part. If one dose is effective, it could make vaccination cheaper and e…

This study tests whether metformin, a standard diabetes medication, can prevent oral cancer in people with precancerous mouth lesions like leukoplakia or erythroplakia. The trial enrolled 26 adults with these lesions and measured if the drug could shrink or eliminate them. The go…

This study looks at whether taking aspirin in different patterns can help prevent colorectal cancer in people who have had colon polyps (adenomas). Aspirin may block certain enzymes that help cancer cells grow. The trial enrolled 81 adults with a history of colon polyps and measu…

This early-phase trial tests a MUC1 peptide vaccine in 50 current or former smokers at high risk for lung cancer. The vaccine aims to train the immune system to recognize and attack precancerous cells before they become cancer. The study focuses on safety and whether the vaccine …

This study tests whether a daily broccoli seed and sprout extract (BSSE) can boost firefighters' natural ability to remove cancer-causing toxins from their bodies. Firefighters are often exposed to harmful chemicals like benzene, which increases their cancer risk. 72 firefighters…

This phase 2 trial tests whether taking aspirin can stop Barrett's esophagus from returning after it has been successfully removed with radiofrequency ablation. About 21 adults who had complete removal of Barrett's esophagus will take either aspirin or a placebo for 12 months. Re…

This study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …

This early-stage study tests an oral drug called ropidoxuridine (IPdR) combined with whole brain radiation in people whose cancer has spread to the brain. The goal is to find the safest dose and see if the drug makes radiation more effective at killing tumor cells. About 11 adult…

This study looks at whether acceptance and commitment therapy (ACT) can improve sleep for adults with sickle cell disease. Participants will have weekly video chats with a coach for 8 weeks and wear a wrist device to track sleep. The goal is to see if this approach is practical a…

This early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…

This study aims to collect DNA samples and health information from 188 people in the U.S. and Canada who have sporadic chordoma, a rare bone cancer. Participants will provide saliva samples and fill out a questionnaire at home. The goal is to find genetic changes that may be link…

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…

This study was designed to understand how well the healthcare system supports adolescents and young adults (ages 12-39) living with advanced cancer. Researchers planned to survey patients, caregivers, and clinicians about their experiences with emotional, spiritual, and communica…

This study tests whether a wearable patch called TempTraq, which continuously monitors body temperature, can detect fever earlier than standard checks in cancer patients receiving immunotherapy. Early detection of fever may help prevent cytokine release syndrome (CRS) from becomi…

This study looks at whether a high-fiber, plant-based diet and regular exercise can change the gut microbiome in people with melanoma who are receiving immunotherapy. Researchers want to see if these lifestyle changes are feasible and if they might affect how well the treatment w…

This study reviews medical records from 1000 people with adrenocortical cancer (ACC), a rare and serious cancer. Researchers want to see how factors like age, sex, race, and how much cancer is in the body relate to survival and treatment success. By looking back at past data, the…

This large study is screening 8,300 people with early-stage non-small cell lung cancer that has been or will be removed by surgery. Researchers collect blood and tumor samples to look for genetic changes. The goal is to help doctors pick the right targeted therapy or immunotherap…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are taken through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is to…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study tests whether a computer algorithm called ENLIGHT can help find better drug matches for people with advanced breast cancer that has stopped responding to standard treatments. About 175 adults with triple-negative or hormone-resistant breast cancer will have their tumor…

This study looks at people and families who have a higher chance of developing blood or lymph node cancers, like leukemia or lymphoma. Researchers want to understand what causes this higher risk, including genetic and environmental factors. Participants provide medical history, b…

This study tested whether routine screening for four cancers (prostate, lung, colorectal, and ovarian) can lower the number of people who die from these diseases. Over 154,000 adults aged 55–74 joined the trial. Researchers compared cancer deaths between those who got screened an…

This study examines tumor tissue from 170 cancer patients who had unusually good responses to treatments that failed for most others. Researchers will analyze the DNA of these tumors to find genetic changes that might explain why these patients did so well. The goal is to discove…

This study follows 259 children and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers track tumors, quality of life, and other health changes to better understand how the disease progresses. The goal is to gather information that can help design future tr…

This study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …

This study creates a bank of blood, cheek cells, semen, urine, or nail clippings from up to 1,200 healthy adult volunteers. The samples are used by scientists for lab research only, such as studying immune function or developing tests. Donors are paid for their time and must be N…

This study looks at whether combining a genetic test called the Oncotype DX Genomic Prostate Score (GPS) with MRI scans can help doctors choose men with prostate cancer for focal therapy—a treatment that targets only the cancer, leaving healthy tissue alone. Researchers will revi…

This study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not in active treatment trials. Participants receive standard medical care while researchers collect health information and samples to build a data repository. The goal is to support future c…

This study collects blood samples from people already in other NIH clinical trials who are having or are expected to have serious side effects from their drugs. The goal is to measure drug levels in the blood to better understand why side effects happen. Up to 100 participants ag…

This study aims to better understand primary liver cancer by collecting blood, urine, stool, and tissue samples from 132 adults who have had or plan to have immunotherapy. Researchers will analyze these samples to learn how the disease develops and progresses. Participants do not…

This early-phase study aims to see if researchers can measure how much of the drug abemaciclib reaches brain tumors and brain fluid in people with aggressive gliomas. Only one participant aged 18-39 with recurrent high-grade or diffuse midline glioma will take the drug for 4.5 da…

This study collects leftover tissue and blood samples from 1,200 adults with known or suspected cancer during their standard surgeries or biopsies. Researchers will compare cancerous and normal tissues to find differences that could lead to new treatments. No extra procedures are…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

This study looks at adults who grew up on farms to see if early exposure to pesticides and other farm-related factors is linked to cancer. Researchers will collect online surveys and biological samples from about 64,000 participants and track their health over many years. The goa…

This study does not offer new treatment. Instead, it follows up to 1,150 people who previously received experimental cell therapies (like growing their own immune cells in a lab and giving them back) for cancers such as melanoma and other tumors. Participants will have physical e…

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study tests whether analyzing the genes of a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers had their tumors genetically tested. Those with specific genetic changes received drugs designed to targe…

This early-stage trial studies how the drug triapine affects uterine cancer cells in 12 women scheduled for hysterectomy. Participants receive triapine before surgery, and researchers measure changes in tumor markers from tissue samples. The goal is to understand if triapine can …

This study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) and compares them to unvaccinated women. Researchers want to see how long the vaccine protects against cervical cancer and whether it might lead to more lesions from other HPV types. …

This study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects, so doctors can better prevent or manage them in future treatments. No new treatments or visits are involved—only existi…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looked at whether screening tests for ovarian cancer can help find the disease early and reduce the number of women who die from it. Over 78,000 women aged 55 to 74 took part. Researchers compared those who got screening to those who got usual care and tracked ovarian …

This study is developing a questionnaire specifically for children and teens (ages 5-17) who have chronic graft-versus-host disease (cGVHD) after a stem cell transplant. The goal is to create a tool that accurately captures how bothersome their symptoms are, since current scales …

This study looks at information already collected from over 566,000 AARP members aged 50 to 71. Researchers want to learn how diet and lifestyle choices are linked to cancer, chronic diseases, and death. No new participants are being recruited, and no treatments are being tested.

This study looked at whether routine screening for prostate, lung, colorectal, and ovarian cancers can lower the number of deaths from these diseases. Over 154,000 people took part, with some getting regular screening and others receiving usual care. The main goal was to see if e…

This study collects blood and urine samples from 1,000 adults who are receiving radiation therapy for cancer. Researchers want to learn how radiation affects genes in white blood cells, damages red blood cells, and changes hormone levels. Samples are taken before, during, and aft…

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study collects blood and bone marrow samples from up to 550 people with blood cancers like leukemia and lymphoma. Researchers will study the samples in the lab to learn more about how these cancers grow and differ from normal cells. The goal is to better understand the disea…

This study explores whether a special PET/CT scan using a radioactive tracer called FLT can help doctors see how well chemotherapy is working in people with acute myeloid leukemia (AML). About 87 adults with newly diagnosed AML will get an FLT PET/CT scan after starting treatment…

This study looked at whether regular screening for prostate, lung, colorectal, and ovarian cancers helps prevent death from these diseases. About 155,000 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers tracked cancer cases…

This study follows up to 500 children who received gene therapy for cancer through the National Cancer Institute. Researchers will monitor them for 15 years to detect any delayed side effects from the treatment. Participants will have regular check-ups and blood tests to track th…

This study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This early-phase study looked at how the body handles two different doses of vorinostat when given with standard chemotherapy drugs (carboplatin or paclitaxel) in 20 adults with advanced solid tumors that had no standard treatment options. The main goal was to measure drug levels…

This study is checking how long the HPV vaccine protects women who received one, two, or three doses. Researchers are following about 946 women from an earlier trial in Costa Rica for up to 20 years after their shots. By testing blood samples, they hope to learn if one dose might…

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…